What is the appropriate postoperative follow‑up schedule, including history, physical exam, laboratory tests (complete blood count, liver panel, CA 19‑9), and imaging (contrast‑enhanced CT or MRI), for a patient treated for gallbladder cancer?

Follow-up of Gallbladder Cancer After Curative Treatment

For patients treated for gallbladder cancer with curative intent, perform contrast-enhanced CT of chest, abdomen, and pelvis along with tumor markers (CA 19-9 and CEA) every 3-4 months in year 1, every 6 months in year 2, and annually thereafter until 5 years post-surgery. 1

Evidence Base and Rationale

The most recent and highest-quality guideline addressing biliary tract cancer follow-up comes from the 2025 EASL Clinical Practice Guidelines on extrahepatic cholangiocarcinoma, which provides specific recommendations applicable to gallbladder cancer as part of the biliary tract cancer spectrum 1. This recommendation is based on the BilCap clinical trial protocol, which established the current standard of care for adjuvant therapy in biliary tract cancers 1.

Specific Follow-up Schedule

Year 1: Every 3-4 months

• History and physical examination focusing on symptoms of recurrence (abdominal pain, jaundice, weight loss, new masses) 1
• Tumor markers: CA 19-9 and CEA (CA 125 may also be considered as it has prognostic value) 1
• Imaging: Contrast-enhanced CT of chest, abdomen, and pelvis (or contrast-enhanced abdominal MRI with chest CT) 1

Year 2: Every 6 months

• Same components as Year 1 1

Years 3-5: Annually

• Same components as Years 1-2 1

After 5 years

• Patients without recurrence may be offered the opportunity to stop structured follow-up 1

Imaging Modality Selection

Contrast-enhanced CT is the preferred imaging modality for comprehensive surveillance, as it evaluates the primary site, regional lymph nodes, liver, and distant metastases in a single study 1. MRI with contrast can be substituted for abdominal imaging when CT is contraindicated, but chest imaging should still be obtained 1.

Important Caveats:

• PET/CT is not recommended for routine surveillance and should only be considered when conventional imaging is negative but there is clinical suspicion of recurrence (e.g., persistently elevated CA 19-9) 1
• Ultrasound alone is inadequate for post-treatment surveillance of gallbladder cancer due to low sensitivity for detecting recurrence 1

Tumor Marker Interpretation

CA 19-9 is the primary tumor marker for gallbladder cancer surveillance 1, 2. The postoperative CA 19-9 level has been shown to be a significant prognostic factor for locoregional control, disease-free survival, and overall survival 2.

Multi-marker approach:

• The combination of CA 19-9, CEA, and CA 125 has demonstrated prognostic value in biliary tract cancers 1
• Testing all three markers should be considered when feasible 1
• Rising tumor markers warrant immediate imaging evaluation even if not scheduled 1

Clinical Examination Focus

At each visit, the physical examination should specifically assess for:

• Jaundice or scleral icterus (suggesting biliary obstruction from recurrence) 1
• Hepatomegaly or right upper quadrant masses (liver metastases or local recurrence) 1
• Ascites (peritoneal carcinomatosis) 1
• Supraclavicular or cervical lymphadenopathy (distant nodal metastases) 1
• Weight loss and performance status (systemic disease progression) 1

Rationale for Intensive Early Surveillance

The surveillance schedule is more intensive in the first 2 years because:

• Recurrence risk is highest in the first 2 years after treatment 1
• Early detection of recurrence may allow for salvage therapy including repeat resection, ablation, or systemic therapy 1
• The BilCap trial, which established current adjuvant therapy standards, used this surveillance schedule 1

Common Pitfalls to Avoid

1. Do not rely on symptoms alone: Many recurrences are asymptomatic initially, and imaging detects disease earlier than clinical symptoms 1

2. Do not skip chest imaging: Gallbladder cancer can metastasize to the lungs, and chest CT should be part of routine surveillance 1

3. Do not continue surveillance indefinitely without clinical benefit: After 5 years without recurrence, the yield of continued intensive surveillance is low, and patients may transition to less frequent or symptom-driven follow-up 1

4. Do not order PET/CT routinely: This is not cost-effective for routine surveillance and should be reserved for problem-solving when conventional imaging is equivocal 1

Supporting Evidence from Other Guidelines

While the EASL 2025 guidelines provide the most recent and specific recommendations 1, the NCCN Guidelines for Biliary Tract Cancers support similar surveillance strategies with imaging every 3-6 months for the first 2 years 3, 4. The ESMO guidelines for biliary tract cancer also endorse regular follow-up with imaging and tumor markers, though with slightly less prescriptive intervals 1.

The expert consensus statement on gallbladder cancer emphasizes that patients with T2-4 disease or N1 disease who undergo R0 resection should receive adjuvant therapy and close surveillance 5, supporting the rationale for intensive monitoring in these higher-risk patients.